CFM
MDGL icon

Cornerstone Financial Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cornerstone Financial Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15K Hold
4
– – ﹤0.01% 821
2026
Q1 		$2.09K Hold
4
– – ﹤0.01% 721
2025
Q4 		$2.33K Buy
+4
New +$2.04K ﹤0.01% 640

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Cornerstone Financial Management's MDGL Position: Q2 2026 in Review

Cornerstone Financial Management held its Madrigal Pharmaceuticals (MDGL) position steady in Q2 2026 at 4 shares worth $2.15K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Cornerstone Financial Management first reported a position in MDGL in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.33K in Q4 2025. 414 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • Cornerstone Financial Management held 4 shares of Madrigal Pharmaceuticals worth $2.15K as of Q2 2026.
  • Cornerstone Financial Management left its Madrigal Pharmaceuticals share count unchanged in Q2 2026.
  • Madrigal Pharmaceuticals made up ﹤0.01% of Cornerstone Financial Management's portfolio in Q2 2026, its #821 holding.
  • Cornerstone Financial Management first reported a position in Madrigal Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Cornerstone Financial Management's Madrigal Pharmaceuticals position peaked at $2.33K in Q4 2025.
  • 414 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Cornerstone Financial Management's 13F filing for Q2 2026, filed 12 Aug 2026.